Lucid Capital Markets Reiterates Buy Rating on Adial Pharmaceuticals

Adial Pharmaceuticals receives a buy rating from Lucid Capital Markets with a $6 target.

Written by EarningsIQ · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 16, 2026, 4:02 PM EDT

Key Points

Lucid Capital Markets reiterated its buy rating on Adial Pharmaceuticals, Inc. (ADIL) with a price target of $6 on June 15, 2026.
Adial Pharmaceuticals, trading at $2.98, has a market cap of about $6.24 million and a 52-week high of $19.00.
Insiders, including the CEO, acquired shares in April 2026, and institutional investors like Geode Capital Management increased their holdings.

Lucid Capital Markets recently reiterated its buy rating on Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL), maintaining a price target of $6. This update was made on June 15, 2026, by analyst Elemer Piros, who continues to see potential in the stock.

Other Institutional Activity in Adial Pharmaceuticals

Geode Capital Management significantly increased its stake in Adial Pharmaceuticals, adding 18,019 shares to hold a total of 24,249 shares valued at approximately $43,405. Vanguard Fiduciary Trust Co also entered the scene with 5,879 shares worth about $10,523. On the other hand, Manchester Capital Management slightly trimmed its position by 1 share, now holding 1,923 shares valued at $3,443, while BlackRock, Inc. similarly reduced its holdings by 1 share, leaving it with 1,110 shares worth $1,987. UBS Group AG expanded its stake by 175 shares, totaling 542 shares with a value of $970.

Adial Pharmaceuticals Stock Snapshot

Shares of NasdaqCM:ADIL are trading around $2.98. Adial Pharmaceuticals has a market capitalization of approximately $6.24 million. The company is not currently profitable, reflected in its negative forward P/E ratio. The stock's 52-week range is between $1.31 and $19.00, with a 50-day moving average of $1.87 and a 200-day moving average of $5.16. The company's current ratio is 3.18, and its quick ratio is 3.04.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

On April 7, 2026, several insiders at Adial Pharmaceuticals, including CEO Cary Claiborne, acquired shares. Claiborne purchased 37,985 shares, while CFO Vinay Shah bought 17,325 shares. COO Tony Goodman acquired 26,510 shares. Other insiders, such as Kevin Schuyler, Robertson Gilliland, and Kermit Anderson, each bought 9,185 shares.

Analysts Set New Price Targets

On June 15, 2026, Lucid Capital Markets reiterated its buy rating on Adial Pharmaceuticals with a $6 price target. Previously, Maxim Group upgraded the stock to a buy on September 30, 2025, setting a target of $1.5. Rodman & Renshaw initiated coverage with a buy rating and an $8 target on November 14, 2024. Currently, the consensus is a buy recommendation with a mean price target of $8 from one analyst opinion.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Glen Allen, Virginia. It focuses on developing treatments for addiction and related disorders. Its lead product, AD04, is in Phase 3 clinical trials for alcohol use disorder. The company also works on non-opioid pain reduction therapies and other medical conditions. Founded in 2010, Adial operates with a small team of five employees under the leadership of CEO Cary John Claiborne.

Bottom Line

Adial Pharmaceuticals continues to catch the attention of analysts, with Lucid Capital Markets reaffirming its positive outlook. The company is a clinical-stage biotech with a focus on treating addiction, a promising area of research. While the stock's current trading price is far below its 52-week high, the reiterated buy rating and insider buying may suggest confidence in its future prospects. As always, it's important to remember that analyst ratings are one piece of the puzzle in evaluating a stock.